GFM
RYTM icon

GF Fund Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

GF Fund Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$130K Buy
1,498
+188
+14% +$18.3K ﹤0.01% 316
2025
Q4 		$140K Sell
1,310
-119
-8% -$12.6K ﹤0.01% 320
2025
Q3 		$144K Sell
1,429
-144
-9% -$13.4K ﹤0.01% 313
2025
Q2 		$99.4K Hold
1,573
– – ﹤0.01% 367
2025
Q1 		$83.3K Buy
1,573
+283
+22% +$15.7K ﹤0.01% 378
2024
Q4 		$72.2K Buy
+1,290
New +$71.3K ﹤0.01% 358

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

GF Fund Management's RYTM Position: Q1 2026 in Review

GF Fund Management increased its Rhythm Pharmaceuticals (RYTM) stake by 14% in Q1 2026, buying an estimated $18.3K and bringing the position to 1,498 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #316.

GF Fund Management first reported a position in RYTM in Q4 2024 and has held it in 6 quarters since. The position peaked at $144K in Q3 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • GF Fund Management held 1,498 shares of Rhythm Pharmaceuticals worth $130K as of Q1 2026.
  • GF Fund Management bought 188 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $18.3K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #316 holding.
  • GF Fund Management first reported a position in Rhythm Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Rhythm Pharmaceuticals position peaked at $144K in Q3 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.